Evidence map›Paper›PMID 37149844›Full record

ArticleMolecular oncology2023

The synthetic oleanane triterpenoid CDDO-2P-Im binds GRP78/BiP to induce unfolded protein response-mediated apoptosis in myeloma.

George Luo, Kristin Aldridge, Toby Chen, Vivek Aslot, Byung-Gyu Kim, Eun Hyang Han, Neelima Singh, Sai Li, Tsan Sam Xiao, Michael B Sporn and 1 more

Open access · goldAbstract read
In one paragraph

Article in Molecular oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

George LuoDepartment of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH, USA.ORCID 0000-0002-0566-2025
Kristin AldridgeTriterpenoid Therapeutics Inc., Tunbridge, VT, USA.
Toby ChenTrinity College of Arts and Sciences, Duke University, Durham, NC, USA.
Vivek AslotDepartment of Chemical and Biomolecular Engineering, Case Western Reserve University, Cleveland, OH, USA.
Byung-Gyu KimThe Angie Fowler Adolescent and Young Adult Cancer Institute, University Hospitals Rainbow Babies & Children's Hospital, Cleveland, OH, USA.ORCID 0000-0002-8921-5061
Eun Hyang HanThe Angie Fowler Adolescent and Young Adult Cancer Institute, University Hospitals Rainbow Babies & Children's Hospital, Cleveland, OH, USA.
Neelima SinghThe Angie Fowler Adolescent and Young Adult Cancer Institute, University Hospitals Rainbow Babies & Children's Hospital, Cleveland, OH, USA.
Sai LiDepartment of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Tsan Sam XiaoDepartment of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Michael B SpornTriterpenoid Therapeutics Inc., Tunbridge, VT, USA.
John J LetterioThe Angie Fowler Adolescent and Young Adult Cancer Institute, University Hospitals Rainbow Babies & Children's Hospital, Cleveland, OH, USA.ORCID 0000-0003-0437-6323
University Hospitals Cleveland Medical Center · USUniversity School · USTunbridge Wells Hospital · GBCase Western Reserve University · USDuke University · US

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007250 · NIGMS · CASE WESTERN RESERVE UNIVERSITY · PI HUANG, ALEX YEE-CHEN · 1985 to 2023
$33.4M
Molecular mechanisms of gasdermin recognition by proteases and autophagy proteins in cytokine releaseP01AI141350 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI DUBYAK, GEORGE R · 2020 to 2024
$9.4M
Development of the New Synthetic Triterpenoid CDDO-2P-IM (TTX01) for Multiple MyelomaR43CA243842 · NCI · TRITERPENOID THERAPEUTICS, INC. · PI SPORN, MICHAEL B · 2019 to 2020
$550k
NCI NIH HHS 1 R43 CA243842-01NCI NIH HHS R43 CA243842NIAID NIH HHS P01 AI141350NIGMS NIH HHS T32 GM007250NIH HHS 5T32GM007250NIH HHS P01AI141350
6 · The paper itself

Abstract

Synthetic oleanane triterpenoids (SOTs) are small molecules with broad anticancer properties. A recently developed SOT, 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]-4(-pyridin-2-yl)-1H-imidazole (CDDO-2P-Im or '2P-Im'), exhibits enhanced activity and improved pharmacokinetics over CDDO-Im, a previous generation SOT. However, the mechanisms leading to these properties are not defined. Here, we show the synergy of 2P-Im and the proteasome inhibitor ixazomib in human multiple myeloma (MM) cells and 2P-Im activity in a murine model of plasmacytoma. RNA sequencing and quantitative reverse transcription PCR revealed the upregulation of the unfolded protein response (UPR) in MM cells upon 2P-lm treatment, implicating the activation of the UPR as a key step in 2P-Im-induced apoptosis. Supporting this hypothesis, the deletion of genes encoding either protein kinase R-like endoplasmic reticulum kinase (PERK) or DNA damage-inducible transcript 3 protein (DDIT3; also known as CHOP) impaired the MM response to 2P-Im, as did treatment with ISRIB, integrated stress response inhibitor, which inhibits UPR signaling downstream of PERK. Finally, both drug affinity responsive target stability and thermal shift assays demonstrated direct binding of 2P-Im to endoplasmic reticulum chaperone BiP (GRP78/BiP), a stress-inducible key signaling molecule of the UPR. These data reveal GRP78/BiP as a novel target of SOTs, and specifically of 2P-Im, and suggest the potential broader utility of this class of small molecules as modulators of the UPR.

Indexed as

Multiple MyelomaAnimalsApoptosisCell Line, TumorEndoplasmic Reticulum Chaperone BiPHumansImidazolesMiceOleanolic AcidUnfolded Protein Response1-(2-cyano-3,12-dioxooleana-1,9-dien-28-oyl) imidazolebardoxoloneEndoplasmic Reticulum Chaperone BiPImidazolesoleananeOleanolic AcidapoptosisCDDO-2P-ImGRP78myelomatriterpenoidUPR

Identifiers

PMID37149844
PMCPMC10701780
OpenAlexW4375855633

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.